Time to second-line treatment and subsequent relative survival in older patients with relapsed CLL/SLL

We investigated whether stratifying by the interval between first-line (T1) and second-line (T2) treatments could identify a subgroup of older patients with relapsed CLL/SLL with an expectation of normal overall survival. Longer time-to-T2 was associated with a modestly improved prognosis; however, even among those retreated ≥3 years after T1, survival was poor compared to the general population (5-year relative survival=50%).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research